Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix ® 30) when switching from human premix insulin in patients with type 2 diabetes: Subgroup analysis from the 6-month IMPROVE™ observational study

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 574-582

  Shah, S ^b   Benroubi, M ^c   Borzi, V ^d   Gumprecht, J ^e   Kawamori, R ^f   Shaban, J ^g   Shestakova, M ^h   Wenying, Y ⁱ   Valensi, P ^a,j  

^a HÔPITAL JEAN VERDIER   (France)

^b SL Raheja Hospital   (India)

^c KAT HOSPITAL   (Greece)

^d UNIVERSITY OF CATANIA   (Italy)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g WINDSOR REGIONAL HOSPITAL   (Canada)

^h N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

ⁱ CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^j UNIVERSITÉ PARIS 13   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; HEMOGLOBIN A1C; HUMAN INSULIN; HUMAN PREMIX INSULIN; INSULIN ASPART; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT REDUCTION;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 62549083402     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02012.x     Document Type: Article

References (26)

1. Walley T, Hughes D, Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992-2003. Pharmacoepidemiol Drug Saf 2005 14 : 769 73.
2. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 diabetes. Brussels : International Diabetes Federation, 2007. http://www.idf.org/home/ index.cfm?node=1457 (accessed December 2008).
3. AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 13 (Suppl. 1 4 68.
4. Boehm BO, Home PD, Kamp BNM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002 19 : 393 9.
5. Hermansen K, Colombo M, Storgaard H, Østergaard A, Kølendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002 25 : 883 8.
6. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007 9 : 630 9.
7. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000 56 : 399 403.
8. Malone JK, Woodworth JR, Arora V et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000 22 : 222 30.
9. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycaemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endo Invest 2009 (in press).
10. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
11. Kann P, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006 114 : 527 32.
12. Liebl A, Prager R, Binz K et al. Comparison of insulin analogue regimens in people with type 2 diabetes in the PREFER study: a randomized controlled trial. Diabetes Obes Metab 2009 11 : 45 52.
13. Garber A, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006 8 : 58 66.
14. Shestakova M, Sharma SK, Almustafa M et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007 23 : 3209 14.
15. Valensi P, Benroubi M, Borzi V et al. The IMPROVE™ study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008 62 : 1809 19.
16. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006 15 : 481 91.
17. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997 20 : 1612 4.
18. Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007 29 (Special issue 1284 92.
19. Gao Y, Guo XH, Vaz JA, PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diabetes Obes Metab 2009 11 : 33 40.
20. Sharma SK, Joshi SR, Kumar A et al. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT Study. JAPI 2008 56 : 859 63.
21. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008 31 (Suppl. 1 S12 54.
22. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008 31 : 1 11.
23. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes 2004 28 (Suppl. 2 S14 22.
24. Brown JB, Nichols GA. Slow response of glycemic control in type 2 diabetes mellitus. Am J Manag Care 2003 9 : 213 7.
25. Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007 5 : 8.
26. Palmer JL, Gibbs M, Scheijbeler HW et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008 25 : 752 74.